Abbott Laboratories (ABT) concentration risks

Abbott Laboratories' sole disclosed concentration is geographic: sales outside of the U.S. in 2025 made up approximately 61 percent of Abbott's net sales. By disclosed size this is a large share, and its character is structural — it reflects where the company's end-markets, manufacturing footprint, and growth opportunities are distributed globally rather than any single customer or supplier relationship. Because the exposure spans many countries and product categories rather than being pinpointed to a single region or counterparty, the risks that flow from it are broad and diffuse: currency translation effects, regulatory environments that vary by jurisdiction, geopolitical developments, and country-specific reimbursement dynamics are the main channels through which this share of non-US revenue could affect reported results. None of these are company-specific shocks; they move with global macro and regulatory cycles. There are no disclosed customer, product, supplier, or sub-regional concentrations disclosed alongside the international sales figure to compound the picture. The profile is therefore well-understood and well-disclosed: a globally distributed business with a large non-US revenue share, without an identifiable single counterparty or territory that could create a pinpointed, abrupt downside if lost. Investors should treat currency movements and international healthcare policy developments — rather than any named customer or geography — as the primary channels through which this exposure translates to earnings variability.

For the engine’s reasoning on ABT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.